Cyclin A as a marker for prognosis and chemotherapy response in advanced breast cancer

We wanted to study cyclin A as a marker for prognosis and chemotherapy response. A total of 283 women with metastatic breast cancer were initially enrolled in a randomised multicentre trial comparing docetaxel to sequential methotrexate-fluorouracil (MF) in advanced breast cancer after anthracycline...

Descripción completa

Detalles Bibliográficos
Autores principales: Poikonen, P, Sjöström, J, Amini, R-M, Villman, K, Ahlgren, J, Blomqvist, C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361595/
https://www.ncbi.nlm.nih.gov/pubmed/16091759
http://dx.doi.org/10.1038/sj.bjc.6602735

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361595/
https://www.ncbi.nlm.nih.gov/pubmed/16091759
http://dx.doi.org/10.1038/sj.bjc.6602735

Ejemplares similares